A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

13504NVL-655-01OpenA Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)NCT05384626IndustrialAdultTreatmentI/IILungReuss, JoshuaGeorgetown University Medical Center : Matt Hayhurst; Lombardi Comprehensive Cancer Center : Matt HayhurstThoracic/CNS/H&N/ThyroidOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS16691Matt HayhurstMatt Hayhurstmh2340@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>